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###### Synopsis

A recently developed quality of life survey identifies quantitative differences between Krabbe disease phenotypes and provides new evidence of the benefit of presymptomatic stem cell transplantation in this condition.

1. INTRODUCTION {#jmd212033-sec-0007}
===============

Knud Krabbe first described the condition that bears his name over 100 years ago.[1](#jmd212033-bib-0001){ref-type="ref"} Krabbe disease (KD), or globoid cell leukodystrophy (OMIM\#245200), was, over the ensuing century, established as a severe, invariably fatal neurologic disorder affecting mainly infants and children.[2](#jmd212033-bib-0002){ref-type="ref"}, [3](#jmd212033-bib-0003){ref-type="ref"}, [4](#jmd212033-bib-0004){ref-type="ref"}, [5](#jmd212033-bib-0005){ref-type="ref"} Yet the natural history and phenotypic progression of this disorder remain incompletely understood.[2](#jmd212033-bib-0002){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"}, [7](#jmd212033-bib-0007){ref-type="ref"} All cases appear to be caused by an autosomal recessive deficiency of the enzyme galacto‐cerebrosidase (GALC),[8](#jmd212033-bib-0008){ref-type="ref"}, [9](#jmd212033-bib-0009){ref-type="ref"} but genotype/phenotype correlation remains poorly elucidated, except for homozygous expression of the 30 kb deletion that predicts early infantile onset Krabbe disease (EIKD).[2](#jmd212033-bib-0002){ref-type="ref"}, [4](#jmd212033-bib-0004){ref-type="ref"}, [10](#jmd212033-bib-0010){ref-type="ref"} Current descriptions of KD phenotype focus upon age of onset, distinguishing EIKD from later onset variants that can emerge in later infancy, childhood, or adulthood.[2](#jmd212033-bib-0002){ref-type="ref"}, [4](#jmd212033-bib-0004){ref-type="ref"}, [5](#jmd212033-bib-0005){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"} But the age demarcations and symptomatic characterization of the later onset variants, as well as their relative proportions, are not defined unequivocally.[7](#jmd212033-bib-0007){ref-type="ref"}

The only currently available therapy for KD is stem cell transplantation (SCT), which, while not curative, modifies phenotype optimally only if used before symptoms develop.[11](#jmd212033-bib-0011){ref-type="ref"}, [12](#jmd212033-bib-0012){ref-type="ref"}, [13](#jmd212033-bib-0013){ref-type="ref"} However, because newborn screening (NBS) for KD has not been widely adopted,[14](#jmd212033-bib-0014){ref-type="ref"} most cases of EIKD currently present with at least mild symptoms. Virtually all late onset cases are identified only after symptoms develop.[6](#jmd212033-bib-0006){ref-type="ref"}, [7](#jmd212033-bib-0007){ref-type="ref"} The need to better define natural history to determine when treatment will be effective is a major challenge not only in KD[7](#jmd212033-bib-0007){ref-type="ref"}, [13](#jmd212033-bib-0013){ref-type="ref"}, [15](#jmd212033-bib-0015){ref-type="ref"}, [16](#jmd212033-bib-0016){ref-type="ref"}, [17](#jmd212033-bib-0017){ref-type="ref"}, [18](#jmd212033-bib-0018){ref-type="ref"} but also more generally in childhood leukodystrophies.[19](#jmd212033-bib-0019){ref-type="ref"}

We report here our utilization of the World Wide Registry (WWR), a data resource that contains information on almost 200 affected or at‐risk cases[2](#jmd212033-bib-0002){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"}, [20](#jmd212033-bib-0020){ref-type="ref"}, [21](#jmd212033-bib-0021){ref-type="ref"} to better define the phenotypes that comprise the natural history of KD variants. The WWR facilitates study of this rare condition.[2](#jmd212033-bib-0002){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"}, [20](#jmd212033-bib-0020){ref-type="ref"}, [21](#jmd212033-bib-0021){ref-type="ref"} Analysis of death certificates suggested a frequency of EIKD of 1 in 244 000 and later onset cases are even more rare.[22](#jmd212033-bib-0022){ref-type="ref"} However, the New York State experience after 10 years of NBS for Krabbe[18](#jmd212033-bib-0018){ref-type="ref"} identified only five definite cases among over 2 million screened.

The need for a broad exploration of quality of life (QOL) as an expression of phenotype became apparent during the course our recent analysis of the effect of SCT upon survival in symptomatic KD patients.[21](#jmd212033-bib-0021){ref-type="ref"} QOL is indeed considered a critical determinant of the response to therapy in KD.[23](#jmd212033-bib-0023){ref-type="ref"} Consequently, we conducted phone surveys of currently surviving patients enrolled in the registry.

2. METHODS {#jmd212033-sec-0008}
==========

2.1. Identification of KD patients {#jmd212033-sec-0009}
----------------------------------

The WWR consists of de‐identified data regarding 198 patients who have been diagnosed with KD, or who, by virtue of concerning genotype or diminished GalC enzyme level, are considered to be at high risk for developing symptoms of KD.[2](#jmd212033-bib-0002){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"}, [21](#jmd212033-bib-0021){ref-type="ref"} The de‐identified data are maintained in the Longitudinal Pediatric Data Resource of the Newborn Screening Translation Research Network.[24](#jmd212033-bib-0024){ref-type="ref"}, [25](#jmd212033-bib-0025){ref-type="ref"} Amongst the 198 registrants, 45 were determined as likely to be living at the onset of this study, based upon our periodic follow‐up calls and information provided by advocacy groups. We were able to successfully reach 33 of these surviving individuals or family members for telephone interviews.

We classified phenotypes according to age of onset.[2](#jmd212033-bib-0002){ref-type="ref"}, [4](#jmd212033-bib-0004){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"}, [21](#jmd212033-bib-0021){ref-type="ref"} Thus, EIKD was considered to emerge between birth and 6 months, and late infantile KD (LIKD) between 7 months and 1 year. Because of the limited sample size, the current analysis pooled those cases presenting after 1 year of life as late onset KD (LOKD), merging as a single group of cases which could be identified as juvenile and adult onset.[2](#jmd212033-bib-0002){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"} Alternative classifications of this very rare[22](#jmd212033-bib-0022){ref-type="ref"} disorder have been advanced. Earlier investigators, for example, suggested that LIKD might emerge as late as age 3 or 4 years.[7](#jmd212033-bib-0007){ref-type="ref"}, [26](#jmd212033-bib-0026){ref-type="ref"} But for the current investigation, we rely on the classification that is supported by earlier analysis of data contained in the WWR.[2](#jmd212033-bib-0002){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"}

The current data set includes 11 EIKD cases, seven LIKD cases, 12 LOKD cases, and three registrants who remain asymptomatic despite genotypes indicating risk for LOKD.[10](#jmd212033-bib-0010){ref-type="ref"} SCT was achieved in cases of EIKD (two before and two after symptoms emerged), LIKD (one after symptoms manifested) and LOKD (three before and three after symptoms appeared). Distinguishing whether cases were either symptomatic or presymptomatic for treatment was accomplished by examining medical records contained in the WWR. However, we acknowledge that the presymptomatic patients may have experienced subtle or early complaints (eg, irritability and clumsiness) that may presage more definite neurologic symptoms (including developmental regression, spasticity and blindness) in the infantile[2](#jmd212033-bib-0002){ref-type="ref"} and late onset[6](#jmd212033-bib-0006){ref-type="ref"} phenotypes. All patients who underwent SCT had documented abnormalities in neurophysiologic and neuroimaging tests prior to the procedure, which preceded development of clinical symptoms. In addition, these patients also had a family history of a sibling with identical mutations who developed and died from symptomatic KD during early childhood.

2.2. Development and validation of the survey {#jmd212033-sec-0010}
---------------------------------------------

QOL has been described as a fundamental component of phenotype in genetic disorders generally,[27](#jmd212033-bib-0027){ref-type="ref"} and specifically in lysosomal disorders and leukodystrophies, the class of disorders that includes KD.[28](#jmd212033-bib-0028){ref-type="ref"}, [29](#jmd212033-bib-0029){ref-type="ref"}, [30](#jmd212033-bib-0030){ref-type="ref"}

Proprietary QOL questionnaires have been applied to various pediatric illnesses, for example, sickle cell disease,[31](#jmd212033-bib-0031){ref-type="ref"} inflammatory bowel disease,[32](#jmd212033-bib-0032){ref-type="ref"} dermatologic conditions,[33](#jmd212033-bib-0033){ref-type="ref"} epilepsy,[34](#jmd212033-bib-0034){ref-type="ref"} autism,[35](#jmd212033-bib-0035){ref-type="ref"} and head injuries.[36](#jmd212033-bib-0036){ref-type="ref"} When considered together, these studies indicate that QOL surveys should be modified for application to specific ages and disease entities.[31](#jmd212033-bib-0031){ref-type="ref"}, [36](#jmd212033-bib-0036){ref-type="ref"}, [37](#jmd212033-bib-0037){ref-type="ref"} Even with such targeting, however, some survey recipients have expressed dissatisfaction with relevance of the questions to their life situations.[36](#jmd212033-bib-0036){ref-type="ref"}

The Vineland Adaptive Behavior Scales have been demonstrated to have utility in assessing QOL in significantly disabled individuals.[38](#jmd212033-bib-0038){ref-type="ref"}, [39](#jmd212033-bib-0039){ref-type="ref"}, [40](#jmd212033-bib-0040){ref-type="ref"} However, like other QOL metrics, the relevance of questions to leukodystrophy patients and families and its extended length makes the Vineland unsuitable for use in this population.

We consequently devised a new survey, named the Leukodystrophy Quality of Life Assessment (LQLA---see Data [S1](#jmd212033-supitem-0001){ref-type="supplementary-material"}), which includes questions relevant to the extreme burden of disability and medical problems experienced by most surviving KD patients.[2](#jmd212033-bib-0002){ref-type="ref"}, [4](#jmd212033-bib-0004){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"}, [21](#jmd212033-bib-0021){ref-type="ref"} Our intent was to construct an open‐access, freely available questionnaire suitable for very disabled individuals (from infancy to adulthood) with a leukodystrophy or similar disorder that could be administered in less than 30 minutes. Some of the specific questions were culled from earlier preliminary surveys developed at the respective institutions of the current authors. The survey is appended. It contains questions about social, communicative, and motor abilities, caretaker satisfaction, and medical and neurological symptoms.

To confirm its validity, the LQLA was compared to the Vineland. Like the Vineland, the LQLA was constructed to provide an overall score, as well as subscores in the communication, daily living, social, and motor domains. Both the LQLA and the Vineland were administered to each of the 33 WWR registrants, or caretakers of nonverbal registrants, whom were reached by phone.

2.3. Statistical analyses {#jmd212033-sec-0011}
-------------------------

The LQLA was assessed for concurrent validity with the Vineland using Pearson correlation analysis. To evaluate internal consistency within the LQLA, Cronbach\'s alpha (which increases with increasing average inter‐item correlation) was computed.[41](#jmd212033-bib-0041){ref-type="ref"} Concurrent validity and internal consistency were examined for all patients with, or at high risk of, KD (N = 33). This maximized the sample size used for the comparison.

Analysis of variance (ANOVA) was utilized to identify overall differences between phenotype (EIKD, LIKD, LOKD), and transplant (no transplant, postsymptomatic, presymptomatic) groups. Duncan\'s multiple range test was used to identify pairwise differences between phenotypic and transplant groups. ANOVA and Duncan\'s multiple range test was performed for the sample of Krabbe cases (N = 30).

Pearson correlations, Cronbach\'s alpha, ANOVA and Duncan\'s multiple range test were performed for the overall survey results and each of the four subscales.

Finally, Fisher\'s exact test was used to identify specific survey items that showed phenotypic differences, with the Benjamini‐Hochberg procedure applied to adjust for multiple comparisons. Differences between the standard Bonferroni method of controlling the false positive rate, which can suppress true positive effects, and the Benjamini‐Hochberg test which limits alpha error inflation or the false discovery rate (chosen here to be *α* = 0.25) are well described.[42](#jmd212033-bib-0042){ref-type="ref"} Fisher\'s exact test was restricted to the sample of Krabbe cases that were not transplanted presymptomatically (N = 25).

The questions of the LQLA were arranged in domains that parallel those of the Vineland; there was an overall score, as well as subscores in the communication, daily living, family/social and motor subscales. Each item was scored as a 0 or 1, where 0 indicated a negative response and 1 indicated a positive response. Positive responses were determined based on the choice indicating the closest proximity to the best QOL. Items regarding speaking words and putting words together were assigned a 0 only if the patient was nonverbal. For the LQLA, the maximum overall score was 41, and maximum subscale scores were respectively 10, 14, 11 and 6 for the communication, daily living, family/social and motor subscales.

3. RESULTS {#jmd212033-sec-0012}
==========

The registrants or caretakers were successfully administered both the LQLA and the Vineland over the course of a single telephone call. The LQLA and Vineland scales were administered, respectively, over periods of 10 to 15 minutes and 15 to 30 minutes. The respondents were told at the onset of each interview that administration of the two questionnaires could be achieved over more than a single call if this was preferable. However, all interviews were completed in a single call.

Correlations (*R* ^2^) between the LQLA and the Vineland total and subscale scores are shown in Table [1](#jmd212033-tbl-0001){ref-type="table"}. Values close to 1 suggest near‐perfect validity. Good to excellent concurrent validity (*R* ^2^ range: 0.5923‐0.9522) was demonstrated for the overall scores of the two surveys, and also for the communication, daily living, and motor subdomains. Fair validity was demonstrated for the group of queries assessing social skills (*R* ^2^ = 0.4975). These results suggest that the LQLA provides additional information beyond the Vineland while maintaining a substantial degree of validity against the Vineland.

###### 

Validity and reliability of LQLA

  Full survey sample (N = 33)[a](#jmd212033-note-0001){ref-type="fn"}            
  --------------------------------------------------------------------- -------- --------
  Overall                                                               0.8631   0.9525
  Communication                                                         0.5923   0.9118
  Daily living                                                          0.7621   0.8950
  Social                                                                0.4975   0.7503
  Motor                                                                 0.9522   0.9418

Age of participants at time of survey (months): 14.5, 29.0, 44.0, 52.0, 65.0, 65.6, 66.3, 67.3, 70.4, 73.9, 77.7, 78.3, 82.1, 92.8, 133.6, 143.5, 148.6, 167.5, 175.1, 186.6, 196.8, 197.1, 208.9, 238.1, 314.4, 373.6, 390.3, 447.8, 451.6, 456.2, 460.1, 645.7, and 664.0.

Table [1](#jmd212033-tbl-0001){ref-type="table"} also includes examination of the reliability/internal consistency of the LQLA using Cronbach alpha values, with values near 1 suggesting strong reliability. Table [1](#jmd212033-tbl-0001){ref-type="table"} shows that the overall score and the scores for the communication, daily living, and motor subscores reflected excellent reliability. The social scales demonstrated good reliability.

Having developed a valid and reliable survey for determining QOL in KD patients, we next evaluated the capacity of the LQLA to identify differences amongst the phenotypic groups based upon age of onset. This analysis, shown in Table [2](#jmd212033-tbl-0002){ref-type="table"}, included only the 25 symptomatic KD patients. For each domain, Table [2](#jmd212033-tbl-0002){ref-type="table"} provides means by phenotype and *P*‐values assessing overall differences between phenotype. Table [2](#jmd212033-tbl-0002){ref-type="table"} also contains groupings for Duncan\'s multiple range test. A superscript of "a" indicates the LO mean is higher than the EIKD; "b" indicates the LO mean is higher than the LIKD mean; "c" indicates no significant phenotypic differences. Because of the small sample size, the EIKD cases were compared to the combined late infantile and later onset cases. Significant differences in QOL were shown between these groups. In terms of the overall and communication scores, the later onset cases had substantially better QOL than those with early infantile onset. Differences in the other QOL domains were not significant among these two age‐of‐onset groups (Table [2](#jmd212033-tbl-0002){ref-type="table"}).

###### 

Phenotypic differences

  Sample of Krabbe cases (N = 30)                                      
  --------------------------------- ------- -------- -------- -------- ---------------------------------------------------------------------------------------
  Overall                           .0175   13.636   17.286   24.167   [a](#jmd212033-note-0002){ref-type="fn"}
  Communication                     .0028   4.1820   5.4290   8.2500   [a](#jmd212033-note-0002){ref-type="fn"} ^,^ [b](#jmd212033-note-0003){ref-type="fn"}
  Daily living                      .0645   4.818    6.5710   8.3330   [a](#jmd212033-note-0002){ref-type="fn"}
  Social                            .6446   3.8182   3.8571   4.5833   [c](#jmd212033-note-0004){ref-type="fn"}
  Motor                             .0369   0.8182   1.4286   3.0000   [a](#jmd212033-note-0002){ref-type="fn"} ^,^ [b](#jmd212033-note-0003){ref-type="fn"}

Indicates LO mean significantly higher than EIKD mean.

Indicates LO mean significantly higher than LIKD mean.

Indicates no significant differences between group means.

We next considered the critical question of the effect of SCT upon QOL.[23](#jmd212033-bib-0023){ref-type="ref"} Here we used the LQLA to determine QOL differences between affected patients transplanted before or after the start of symptoms, and those who were never treated with SCT. These results are summarized in Table [3](#jmd212033-tbl-0003){ref-type="table"}. For each domain, Table [3](#jmd212033-tbl-0003){ref-type="table"} provides means by phenotype and *P*‐values assessing overall differences between transplant times. For Duncan\'s multiple range test, a superscript of "a" indicates the presymptomatic transplant group mean is higher than the nontransplant group, and "b" indicates the presymptomatic mean is higher than the postsymptomatic mean. The enhancement of QOL by application of SCT before emergence of symptoms was striking. Presymptomatic transplantation resulted in significant and quantifiable enhancement of QOL compared with either postsymptom or nontransplanted patients in overall scores (82% of maximal scores) and each of the four subscales. In transplanted patients, communication, daily living, social/family and motor scores were respectively 96%, 86%, 40% and 83% of maximum QOL scores. This suggests that while transplanted patients score highly in most QOL domains, the social/family domain may be resistant to QOL improvements brought on by successful transplant.

###### 

Differences between transplant groups

  Sample of Krabbe cases (N = 30)                                       
  --------------------------------- ------- -------- -------- --------- ---------------------------------------------------------------------------------------
  Overall                           .0029   15.526   17.167   32.6000   [a](#jmd212033-note-0005){ref-type="fn"} ^,^ [b](#jmd212033-note-0006){ref-type="fn"}
  Communication                     .0178   5.0530   6.5000   9.6000    [a](#jmd212033-note-0005){ref-type="fn"} ^,^ [b](#jmd212033-note-0006){ref-type="fn"}
  Daily living                      .0142   5.5000   5.789    11.2000   [a](#jmd212033-note-0005){ref-type="fn"} ^,^ [b](#jmd212033-note-0006){ref-type="fn"}
  Social                            .0219   3.526    3.833    6.8000    [a](#jmd212033-note-0005){ref-type="fn"} ^,^ [b](#jmd212033-note-0006){ref-type="fn"}
  Motor                             .0042   1.1580   1.3333   5.0000    [a](#jmd212033-note-0005){ref-type="fn"} ^,^ [b](#jmd212033-note-0006){ref-type="fn"}

Indicates presymptomatic transplant mean significantly higher than no‐transplant mean.

Indicates presymptomatic transplant mean significantly higher than postsymptomatic transplant mean.

Because we report here development of a new survey designed to determine QOL in infants and children severely affected with neurologic disability, we considered it of interest to determine which items of the survey contribute most to identification of differences between the phenotypic subgroups. This analysis is shown in Table [4](#jmd212033-tbl-0004){ref-type="table"}, with low *P*‐values suggesting differences between the phenotypes. Shown there is a ranked order of significance for the seven questions that accounted best for differences in QOL between the early infantile, late infantile and late onset phenotypic groups. These groups were distinguished between each other most prominently by items that are related to communication. Only one of the seven items, the capacity to roll over independently, can be considered to represent an exclusively motor ability.

###### 

LQLA items significantly associated with phenotype

  Fisher\'s exact test for item response by phenotype excluding presymptomatic transplants (N = 25)                           
  --------------------------------------------------------------------------------------------------- ------- ------- ------- -------
  Communicates needs                                                                                  77.78   51.14   0       .0019
  Attends school                                                                                      75      42.86   0       .0030
  Babbles                                                                                             100     42.86   33.33   .0056
  Speaks words                                                                                        88.89   71.43   22.22   .0149
  Rolls over                                                                                          100     71.43   44.44   .0237
  General communication                                                                               100     71.43   44.44   .0237
  Smiles                                                                                              66.67   14.29   11.11   .0403

4. DISCUSSION {#jmd212033-sec-0013}
=============

These results establish the LQLA as a valid and reliable survey for determining QOL in KD (Table [1](#jmd212033-tbl-0001){ref-type="table"}), and presumably also for any disorder which causes a similar impairment of neurologic function. It may consequently find use in future research that examines benefits of therapies for neurodegenerative disorders, in which QOL is indeed recognized as an important outcome of treatment.[28](#jmd212033-bib-0028){ref-type="ref"}, [29](#jmd212033-bib-0029){ref-type="ref"}, [30](#jmd212033-bib-0030){ref-type="ref"} It is possible that the survey could be shortened to include the items contributing most to the KD phenotypic difference (Table [4](#jmd212033-tbl-0004){ref-type="table"}). However, determination of its final iteration will require testing more broadly in KD and other neurodegenerative illnesses.

We acknowledge that the major shortcoming of the current study is the small sample size. It must, however, also be acknowledged that KD is extremely rare.[18](#jmd212033-bib-0018){ref-type="ref"}, [22](#jmd212033-bib-0022){ref-type="ref"} The possibility of reaching 30 living, affected patients for phone interviews, made possible by their registration in the WWR, provided an opportunity to better understand phenotypic expression of this very rare disorder.

The findings above (Table [2](#jmd212033-tbl-0002){ref-type="table"}), which compare QOL in time of onset‐based groups (EIKD and later onset cases), provide new, quantitative distinctions between these phenotypes. The natural history of EIKD, therefore, can be concluded to involve certain identifiable components of QOL more prominently than in patients who experience later onset of symptoms. However, the QOL differences between phenotype were not observed on the social domain. This may indicate that social experiences are common between phenotypes.

This line of inquiry was continued by examination of the specific contribution of types of survey questions that contributed to the differences between ages of onset‐based phenotypes (Table [4](#jmd212033-tbl-0004){ref-type="table"}). The greatest differences between these phenotypes were attributable to communication skills. KD primarily affects the white matter of the brain and peripheral nerves, parts of the nervous system that are not primarily associated with neurocognitive capacities, but cognition may be affected prominently in the early stages of the disorder.[2](#jmd212033-bib-0002){ref-type="ref"}, [4](#jmd212033-bib-0004){ref-type="ref"}, [6](#jmd212033-bib-0006){ref-type="ref"} KD indeed results in extensive involvement of white matter tracts but also atrophy of cerebral gray matter.[43](#jmd212033-bib-0043){ref-type="ref"}, [44](#jmd212033-bib-0044){ref-type="ref"}

In addition, the current findings are consistent with a recent report by others identifying outcomes of SCT in KD,[13](#jmd212033-bib-0013){ref-type="ref"} where it was found that the treatment specifically preserves cognitive abilities and results in improvement of receptive language skills, even as motor disability may advance in treated patients.[13](#jmd212033-bib-0013){ref-type="ref"} These results are concordant with the current finding that more severely affected patients have diminished QOL in the realm of communication skills (Table [4](#jmd212033-tbl-0004){ref-type="table"}).

The benefit of SCT for KD was also addressed by the current study of QOL. The enhancement of overall QOL survey scores, as well as of scores in each of the individual communication, daily living, social and motor domains, provide new, strikingly significant proof of the benefit of presymptomatic transplantation (Table [3](#jmd212033-tbl-0003){ref-type="table"}).

However, an alternative explanation for the apparent benefit of presymptomatic transplantation would be that these patients were incorrectly diagnosed prior to treatment; that they represented either false positives or possible later onset cases who were not destined to develop symptoms. While this possibility cannot be absolutely excluded, it is extraordinarily unlikely. Selection of candidates for transplantation is based upon several parameters, including family history, enzyme activity, genotype, and the presence of active, if presymptomatic disease on neurophysiologic and neuroimaging testing prior to transplantation.[11](#jmd212033-bib-0011){ref-type="ref"}, [12](#jmd212033-bib-0012){ref-type="ref"}, [13](#jmd212033-bib-0013){ref-type="ref"}

The current and recently published results[13](#jmd212033-bib-0013){ref-type="ref"} regarding outcomes of SCT may have important implications for Krabbe NBS. Thus, even though screening for KD is now conducted in a few states,[14](#jmd212033-bib-0014){ref-type="ref"} this condition was rejected for inclusion in the recommended universal NBS panel in the United States. Reasons cited for this rejection included insufficient knowledge about KD in three specific areas: the benefit of SCT, the need for a better understanding of the EIKD phenotype, and for an improved approach to diagnosis.[45](#jmd212033-bib-0045){ref-type="ref"}

SCT enhances duration of survival in KD.[11](#jmd212033-bib-0011){ref-type="ref"}, [21](#jmd212033-bib-0021){ref-type="ref"} But unequivocal improvement in specific symptoms remained an open question until recent research into the outcomes of transplanted patients.[13](#jmd212033-bib-0013){ref-type="ref"} The current results (Table [3](#jmd212033-tbl-0003){ref-type="table"}) confirm quantifiable QOL improvement in presymptomatically transplanted patients. Hence, the gap of information regarding the benefit of SCT that was cited in rejection of Krabbe for universal screening[45](#jmd212033-bib-0045){ref-type="ref"} has now been substantially filled.

The data shown in Tables [2](#jmd212033-tbl-0002){ref-type="table"} and [4](#jmd212033-tbl-0004){ref-type="table"} that compared EIKD cases with those having later onset indicated that among aspects of QOL that were surveyed, those specifically related to communication skills accounted for phenotypic differences. The results of this article, therefore, improve phenotypic definition of EIKD.

The final area of incomplete information that precluded universal NBS for KD[45](#jmd212033-bib-0045){ref-type="ref"} is that of accurate and rapid diagnosis. Because of the initially high false positive rate and low positive predictive value of the Krabbe NBS protocol developed in New York state,[14](#jmd212033-bib-0014){ref-type="ref"}, [18](#jmd212033-bib-0018){ref-type="ref"} enthusiasm for NBS for KD was limited. However, learning from this initial experience and recent approaches using biomarkers of infantile KD suggest that rapid diagnosis of the newborn with early infantile disease is possible using a combination of NBS assays, enzyme and psychosine levels.[13](#jmd212033-bib-0013){ref-type="ref"}, [15](#jmd212033-bib-0015){ref-type="ref"}, [17](#jmd212033-bib-0017){ref-type="ref"}, [46](#jmd212033-bib-0046){ref-type="ref"} The results presented here, on the one hand, provide a clearer picture of the phenotypic expression of KD, and of the response of affected patients to current treatment. They may, on the other hand, become part of a broader body of the experimental evidence used to establish the feasibility of NBS for this dreadful affliction of children in the future.
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